Want to join the conversation?
$ABBV updated its EPS guidance to include impact of Stemcentrx acquisition, which is expected to be $0.20 dilutive in 2016. As result, $ABBV now sees adjusted EPS of $4.62-4.82 for 2016, representing 10% growth versus 2015 at the midpoint. $ABBV's EPS guidance is $3.87-4.07 on a GAAP basis.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.